What It Is
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH), commonly described as ACTH(4-7)-Pro-Gly-Pro or an ACTH(4-10) analog depending on the source.[1] It was developed in Russia and is studied mainly as a nootropic and neuroprotective compound, with research focused on stroke recovery, cognition, and brain-derived neurotrophic factor (BDNF) signaling.
Like Selank, Semax has a history of clinical use and regulatory standing in Russia — it appears on that country's list of essential medicines — but this does not carry over to U.S. regulatory status, where no equivalent approval exists.[2]
How It Works
Semax's proposed mechanism centers on brain-derived neurotrophic factor and its receptor, trkB. In rat hippocampus studies, Semax altered BDNF/trkB expression, and other preclinical work has linked it to dopaminergic and serotoninergic signaling, along with changes in immune- and vascular-related gene expression during ischemic brain injury.[3] Semax also belongs to the broader ACTH-fragment and melanocortin research family, though it is described as lacking the hormonal activity of full-length ACTH.[4]
These are overlapping, only partly understood pathways studied almost entirely in animal and cell models — biologically interesting, but not proof of a defined clinical mechanism in people.
What the Research Shows
Human evidence for Semax is limited and concentrated in Russian clinical literature. A 1997 study evaluated Semax in 30 patients during acute ischemic stroke, using daily doses of 12 mg for moderate strokes and 18 mg for severe strokes, compared against 80 conventionally treated controls.[5] A later study reported that Semax combined with early stroke rehabilitation was associated with higher plasma BDNF and faster functional recovery.[6]
A small 2018 neuroimaging study measured brain activity by fMRI in 14 people given intranasal Semax versus 10 given placebo, reporting short-term changes in default-mode network activity — an interesting signal, but far from proof of cognitive enhancement.[7] Broader claims about focus, memory, or mood in healthy users rest mainly on preclinical rodent data and small studies like these, not large controlled human trials.
Safety & Side Effects
Semax has no FDA-approved label, so there is no standardized adverse-event profile drawn from large regulated trials. Available human studies report general tolerability, but the FDA has flagged Semax-related compounded substances as a safety concern, citing potential immunogenicity, aggregation, peptide-related impurities, and a lack of adequate safety information for the routes commonly proposed — chiefly intranasal, but also injectable.[8]
Nasal irritation is a plausible route-specific issue given direct mucosal contact, and drug-interaction data involving antidepressants, stimulants, or other CNS-active medications are essentially absent. Pregnancy, breastfeeding, and long-term safety remain uncharacterized in the sources reviewed.
Regulatory Status: Russia vs. FDA
Semax is not FDA-approved. It does not appear in FDA approval databases such as the Orange Book, and FDA materials instead discuss Semax-related bulk substances in the context of compounding risk rather than approved prescribing information.[8][9]
This differs sharply from its status in Russia, where Semax has a longer history of clinical use and appears on the country's essential-medicines list.[2] That regional approval does not transfer to the United States or other jurisdictions; regulatory status, manufacturing oversight, and clinical evidence standards are separate frameworks, and products sold in the U.S. as "Semax" are unapproved research chemicals rather than reviewed medicines.